Current Report Filing (8-k)
January 13 2017 - 6:13AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
January 13, 2017
AKERS
BIOSCIENCES, INC
.
(Exact
name of registrant as specified in its charter)
New
Jersey
|
|
333-190456
|
|
22-2983783
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
201
Grove Road
Thorofare,
NJ 08086
(Address
of Principal Executive Offices)
(856)
848-2116
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
8.01 Other Events.
On
January 13, 2017, Akers Biosciences, Inc., a New Jersey corporation (the “Company”), issued a press release announcing
that Joseph Gunnar & Co., LLC, the underwriter in the Company’s public offering announced in a Current Report on Form
8-K filed with the Securities and Exchange Commission on January 10, 2017, has elected to exercise its over-allotment option,
pursuant to its underwriting agreement with the Company, to purchase an additional 122,500 shares of the Company’s common
stock at a price of $1.20 per share, before deducting underwriting discounts and commissions, and additional warrants to
purchase up to 61,250 shares of the Company’s common stock with an exercise price of $1.50.
Item
9.01 Financial Statements and Exhibits.
Exhibit
No.
|
|
Description
|
|
|
|
Exhibit
99.1
|
|
Press
Release issued by the Company entitled “Issue of Equity,” dated January 13, 2017.*
|
*
filed
herewith
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AKERS BIOSCIENCES, INC.
|
|
|
|
Date:
January 13, 2017
|
By:
|
/s/
John J. Gormally
|
|
|
John
J. Gormally
|
|
|
Chief
Executive Officer
|
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Aug 2024 to Sep 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Sep 2023 to Sep 2024